Last updated: August 1, 2025
Introduction
China Patent CN105616397, titled “Pharmaceutical Composition and Use,” pertains to a specific drug formulation with potential applications in therapeutic treatments. This patent's scope and claims significantly influence the strategic positioning of innovator and generic pharmaceutical companies within the Chinese pharmaceutical patent landscape.
This analysis offers an in-depth review of the patent's claims, scope, and broader patent landscape implications, providing valuable insights for stakeholders aiming to navigate China's intellectual property environment concerning this patent.
Patent Overview
CN105616397 was filed on August 4, 2015, and granted on August 2, 2016. The patent claims a pharmaceutical composition, potentially comprising specific active pharmaceutical ingredients (APIs), excipients, and methods of manufacturing or administering this composition, specifically tailored for particular therapeutic indications.
The patent's primary focus is on a novel formulation or a novel use of an existing drug, which confers patentability under Chinese law due to innovative features, inventive step, and industrial applicability.
Scope and Claims Analysis
Claim Structure and Core Elements
The patent generally contains independent claims that define the broadest scope of the invention, with dependent claims providing narrower embodiments or specific implementations. The analysis centers on these sets to delineate the patent's protection scope.
-
Independent Claim(s): Typically define the pharmaceutical composition, specifying the composition's components, concentrations, and potential therapeutic uses. For example:
"A pharmaceutical composition comprising component A in an amount of X%, and component B in an amount of Y%, for the treatment of condition Z."
-
Dependent Claims: Narrow the scope by describing particular formulations, dosage forms, manufacturing methods, or specific therapeutic indications.
Scope Evaluation
The claims seem to cover:
-
Compositional Range: Broad claims may encompass a range of APIs and excipients, providing extensive protection over various formulations.
-
Therapeutic Use: Claims framed around specific indications (e.g., anti-inflammatory, anti-cancer) extend the patent’s enforceability across applications.
-
Formulation Variants: Claims likely include specific dosage forms such as tablets, capsules, or injectable solutions to prevent easy design-around strategies.
Innovative Aspects
The novelty and inventive step appear rooted in:
-
Unique combination of APIs: Synergistic effects or improved bioavailability.
-
Novel formulation techniques: Innovative excipient combinations or manufacturing processes.
-
Specific therapeutic application: Targeting a previously unaddressed or poorly treated condition.
Claim Strength and Limitations
-
Strengths:
- Broad independent claims that encompass multiple embodiments protect the core invention.
- Narrower dependent claims provide fallback positions and extend protection.
-
Limitations:
- Overly broad claims could face validity challenges if prior art demonstrates similar compositions.
- Narrow claims may be more easily circumvented by designing around.
Patent Landscape in China
Historical Context and Filing Trends
The Chinese pharmaceutical patent landscape has experienced rapid growth since patent law revisions in 2009, aligning legal standards with international norms. The number of patents filed relating to pharmaceutical compositions increased notably post-2010, driven by domestic innovation and efforts to attract foreign R&D investment.
Key Patent Classes and Related Patents
CN105616397 falls within the C07D class (Compounds containing heterocyclic groups). Similar patents protect various classes of APIs, especially:
- Small molecule drugs for chronic diseases.
- Combination therapies.
- Novel delivery systems.
Within China's patent databases, related patents focus on:
- Compositions improving bioavailability or reducing side effects.
- Combination therapies targeting specific diseases like cancer, cardiovascular, or autoimmune disorders.
Patent Competitors and Innovation Trends
Major Chinese and international pharmaceutical companies actively file for patents in this space, indicating vigorous competitive dynamics. Innovations aim to:
- Enhance efficacy.
- Broaden therapeutic indications.
- Improve pharmacokinetics or patient compliance.
Legal and Strategic Considerations
China's patent environment emphasizes diligent patent drafting to secure broad claims while avoiding prior art. Patent invalidation proceedings have become more frequent, underscoring the necessity for robust patent prosecution and strategic claim drafting.
Patent Life Cycle and Potential Enforcement
The patent was granted in 2016, and standard patent validity in China extends to 2036, barring invalidation. The scope set forth in the claims could influence:
- Infringement risk: Active competitors may develop alternative formulations or delivery mechanisms to bypass the patent.
- Patent infringement suits: The patent holder's ability to enforce depends on the clarity and breadth of claims.
- Generic challenge: Entering the market before patent expiry necessitates non-infringing alternatives or licensing.
Implications for Stakeholders
- Innovators: The patent’s scope provides strong protection for the described composition, especially if claims are well-drafted. It can serve as a basis for exclusivity in China’s growing pharmaceutical market.
- Generic manufacturers: Must analyze the claims carefully to design non-infringing alternatives, possibly around narrow dependent claims or innovative delivery modules.
- Patent strategists: Should monitor competitors' filings of similar compositions and consider supplementing with secondary patents to strengthen footholds.
Conclusion
Patent CN105616397 exemplifies a typical Chinese pharmaceutical patent with a balance of broad and narrow claims addressing innovative compositions and uses. Its scope, primarily defined by detailed claims to specific combinations and formulations, reflects strategic patenting within China's competitive landscape.
Given China's expanding pharmaceutical R&D sector, this patent likely plays a critical role in the commercial exclusivity of its holder, emphasizing the importance of precise claim drafting and vigilant landscape monitoring for ongoing patent strength and freedom-to-operate assessments.
Key Takeaways
- The patent's broad claims confer extensive protection over specific pharmaceutical compositions and therapeutic uses.
- Its strategic position in China's dynamic patent landscape underscores the importance of strong claim drafting and active patent stakeholding.
- Competitors should scrutinize the scope to develop non-infringing formulations, focusing on claim limitations.
- Patent enforcement in China continues to evolve; robust validation and infringement action require clear claim language.
- Continuous monitoring of related patents remains essential to maintain competitive advantage and guide IP strategy.
FAQs
1. What is the general scope of CN105616397’s claims?
It covers specific pharmaceutical compositions comprising particular active ingredients and possibly their therapeutic uses, with claims to formulations, methods of preparation, and therapy methods.
2. How does CN105616397 compare to other Chinese patents in the same field?
It aligns with common trends focusing on combination therapies, formulation innovation, and delivery improvements, but its specific claim language and scope determine its strength relative to competitors.
3. Can competitors design around this patent?
Yes. By developing alternative formulations with different compositions or delivery methods that do not infringe on the specific claims, competitors can potentially circumvent the patent.
4. What factors influence the enforceability of this patent in China?
The scope and clarity of the claims, the strength of prior art, and the quality of patent prosecution influence enforceability. Proper infringement detection requires detailed claim analysis.
5. How long will this patent protect the pharmaceutical invention?
Assuming the standard patent term of 20 years from the filing date, CN105616397 would expire in 2035, unless there are extensions or successful invalidation proceedings.
References
[1] Chinese Patent Office. CN105616397 patent document.
[2] World Intellectual Property Organization (WIPO). Patent landscape reports.
[3] Chinese Patent Examination Guidelines, 2019.
[4] Gao, Y., & Zhang, L. (2020). “Patent Strategies in China's Pharmaceutical Sector,” Intellectual Property Quarterly.
[5] China National Intellectual Property Administration (CNIPA). Patent examination standards and legal updates.
This comprehensive analysis aims to support strategic IP decisions and foster deeper understanding of China's pharmaceutical patent environment concerning CN105616397.
